<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206102</url>
  </required_header>
  <id_info>
    <org_study_id>5077IL/0089</org_study_id>
    <secondary_id>D1441C00089</secondary_id>
    <nct_id>NCT00206102</nct_id>
  </id_info>
  <brief_title>A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder</brief_title>
  <official_title>A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic
      potential of quetiapine fumarate (SEROQUEL) compared with that of a putative
      non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being
      conducted to fulfill the SEROQUEL Phase IV commitment regarding evaluation of cataractogenic
      potential.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the Lens Opacities Classification System II (LOCS II ) Grading Scale</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>Presence of C type of cataractogenic potential event in participant was defined if any LOCS II grades of 2, 3, 4, 5 (with any grade of 0, trace,1 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0= no cataract; 5 is worst. There are no subscales. 0 is the best, 5 is the worst.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of a Nuclear Opalescence (N) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>Presence of N type of cataractogenic potential event in Participants was defined if any LOCS II grades of 2, 3, 4 (with grade at rand equals 0,1), or if the LOCS II grades of 3,or 4 (with grade at randomization=2) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0 is the best, 4 is the worst.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of a Posterior Subcapsular (P) Type Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>Presence of P type of cataractogenic potential event in participant was defined if any LOCS II grades of 1, 2, 3 , 4 (with grade=0 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0 is the best, 4 is the worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Positive and Negative Syndrome Scale (PANSS) Total Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>PANSS total score equals sum of the 30-items scores (range: 30-210). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree. Change in PANSS total score : total score at month 24 minus total score at randomization.Alleviation of psychotic symptoms are indicated by a negative change in PANSS total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PANSS Positive Subscale Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>PANSS Positive subscale score equals sum of the 7-items scores(range:7-49). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PANSS Negative Subscale Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>PANSS Negative subscale score equals sum of the 7-items scores(range:7-49). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree. Change in PANSS Negative subscale score:score at month 24 minus score at randomization. Alleviation of negative psychotic symptoms are indicated by a negative change score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PANSS Psychopathology Subscale Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>PANSS psychopathology subscale score equals sum of the 16-items scores(range:16-112). Each item has ( 1-7 units),1= &quot;absent&quot; psychosis symptom, 7= &quot;extreme&quot; symptom degree.Change in PANSS psychopathology subscale:score at month 24 minus score at randomization. Alleviation of general psychopathology symptoms are indicated by a negative change score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>CGI-S score is accessed on a seven-graded scale ranging from most extremely ill/ very much worse (7) to normal/very much improved (1) , 1 is best. Change : score at month 24 minus score at randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q SF) Total Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>Q-LES-Q total score is the sum of the 16 times of Q-LES-Q SF(range:16-80).Each item has a 5 point satisfaction level scale:from 1=very poor(worst value) to 5=very good(best).Larger values indicate a higher perceived quality of life enjoyment and satisfaction.Change in Q-LES-Q total score:total score at month 24 minus total score at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Personal Evaluation of Transitions in Treatment (PETiT) Total Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>PETiT total score is the sum of the 30 items of PETiT questionnaire(range:0-60) on subjects perceived well-being, adherence, tolerability, satisfaction with treatment. Each item is rated by participant with a 3 point frequency scale:2=often, 1=sometimes, 0=never.Change in PETiT total score: total score at month 24 minus total score at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses of Schizophrenia or Schizoaffective Disorder</measure>
    <time_frame>At Month 24</time_frame>
    <description>Relapse is defined as a hospital stay for psychiatric symptoms or a 2-point increase from baseline in the CGI severity score. CGI-S score ranges from 0-7 with 0 = Not Assessed, 1 = Normal, not at all and 7 = Among the most extremely ill subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Simpson-Angus Scale (SAS) Total Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>SAS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4, higher scores indicate greater severity of Parkinsonian symptoms. Change : total score at month 24 minus total score at randomization. Increase in Change of total score indicates an increase in extrapyramidal motor symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Barnes Akathisia Rating Scale (BARS) Global Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>BARS global score is the 4th individual-item score on the BARS scale, the Global Assessment of Akathisia, with the score ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Change : score at month 24 minus score at randomization. Increase in Change of BARS global score indicates an increase in akathisia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Abnormal Involuntary Movement Scale (AIMS) Total Score</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>AIMS total score is the sum of the 10 individual-item scores(range:0-40), with the score for each item ranging from 0 to 4. Change : total score at month 24 minus total score at randomization. Increase in Change of total score indicates an increase in abnormal voluntary movements. The lower score means lower intensity of abnormal voluntary Movements. 0 is best, 4 is worst. Increase in Change of total score indicates an increase in abnormal voluntary Movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potential Extrapyramidal Symptoms (EPS)</measure>
    <time_frame>From start of the study treatment to last dose plus 30 days</time_frame>
    <description>Number of participants with adverse events potentially associated with EPS collected by MedDRA Preferred Terms as akathisia, bradykinesia, drooling, dyskinesia, dystonia, extrapyramidal disorder, grimacing, muscle rigidity, parkinsonism, restlessness, tardive dyskinesia, tremor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1098</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine fumarate</intervention_name>
    <description>flexible dose oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Seroquel</other_name>
    <other_name>ICI 204,636</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>flexible dose oral</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age 18 to 65

          -  Both Eyes present with lenses intact (no previous cataract extractions)

          -  Stable place of residency

        Exclusion Criteria:

          -  History of corneal surgery

          -  Legal blindness (defined as best corrected visual acuity of 20/200 or worse in one or
             both eyes

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Seroquel Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mabelvale</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morrilton</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Britian</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ft Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>W. Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oak Brook Terrace</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beechwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medina</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>October 22, 2009</results_first_submitted>
  <results_first_submitted_qc>June 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2011</results_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A 24-month, multi-center, evaluator masked (ophthalmologist), open-label, flexible-dose, parallel-group study, 82 sites recruited Sept 2003 through Oct 2008. In total 1099 participants were randomized by Interactive Voice Response System (IVRS). One excluded participant was randomized before the rand visit, and never returned to any study visits.</recruitment_details>
      <pre_assignment_details>Screening for eligibility and must be cross-tapered off of all previous antipsychotic medications</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine Fumarate</title>
          <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="596"/>
                <participants group_id="P2" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="315"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>None of those categories</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine Fumarate</title>
          <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="596"/>
            <count group_id="B2" value="502"/>
            <count group_id="B3" value="1098"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="331"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Participants in the United States (USA) randomized by the study's Interactive Voice Response System (IVRS).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the Lens Opacities Classification System II (LOCS II ) Grading Scale</title>
        <description>Presence of C type of cataractogenic potential event in participant was defined if any LOCS II grades of 2, 3, 4, 5 (with any grade of 0, trace,1 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0= no cataract; 5 is worst. There are no subscales. 0 is the best, 5 is the worst.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The 2-year eye per protocol (E2PP) analysis included all randomized participants who met eye eligibility, had a valid baseline LOCS II evaluation, had reached the study endpoint of either a LOCS II identified cataractogenic potential event or dosed for 21 months without a LOCS II event, and had no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the Lens Opacities Classification System II (LOCS II ) Grading Scale</title>
          <description>Presence of C type of cataractogenic potential event in participant was defined if any LOCS II grades of 2, 3, 4, 5 (with any grade of 0, trace,1 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0= no cataract; 5 is worst. There are no subscales. 0 is the best, 5 is the worst.</description>
          <population>The 2-year eye per protocol (E2PP) analysis included all randomized participants who met eye eligibility, had a valid baseline LOCS II evaluation, had reached the study endpoint of either a LOCS II identified cataractogenic potential event or dosed for 21 months without a LOCS II event, and had no major protocol deviations.</population>
          <units>Participants with C type event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Presence of a Nuclear Opalescence (N) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale</title>
        <description>Presence of N type of cataractogenic potential event in Participants was defined if any LOCS II grades of 2, 3, 4 (with grade at rand equals 0,1), or if the LOCS II grades of 3,or 4 (with grade at randomization=2) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0 is the best, 4 is the worst.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The 2-year eye per protocol (E2PP) analysis included all randomized participants who met eye eligibility, had a valid baseline LOCS II evaluation, had reached the study endpoint of either a LOCS II identified cataractogenic potential event or dosed for 21 months without a LOCS II event, and had no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of a Nuclear Opalescence (N) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale</title>
          <description>Presence of N type of cataractogenic potential event in Participants was defined if any LOCS II grades of 2, 3, 4 (with grade at rand equals 0,1), or if the LOCS II grades of 3,or 4 (with grade at randomization=2) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0 is the best, 4 is the worst.</description>
          <population>The 2-year eye per protocol (E2PP) analysis included all randomized participants who met eye eligibility, had a valid baseline LOCS II evaluation, had reached the study endpoint of either a LOCS II identified cataractogenic potential event or dosed for 21 months without a LOCS II event, and had no major protocol deviations.</population>
          <units>Participants with N type event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Presence of a Posterior Subcapsular (P) Type Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale</title>
        <description>Presence of P type of cataractogenic potential event in participant was defined if any LOCS II grades of 1, 2, 3 , 4 (with grade=0 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0 is the best, 4 is the worst.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The 2-year eye per protocol (E2PP) analysis included all randomized participants who met eye eligibility, had a valid baseline LOCS II evaluation, had reached the study endpoint of either a LOCS II identified cataractogenic potential event or dosed for 21 months without a LOCS II event, and had no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of a Posterior Subcapsular (P) Type Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale</title>
          <description>Presence of P type of cataractogenic potential event in participant was defined if any LOCS II grades of 1, 2, 3 , 4 (with grade=0 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0 is the best, 4 is the worst.</description>
          <population>The 2-year eye per protocol (E2PP) analysis included all randomized participants who met eye eligibility, had a valid baseline LOCS II evaluation, had reached the study endpoint of either a LOCS II identified cataractogenic potential event or dosed for 21 months without a LOCS II event, and had no major protocol deviations.</population>
          <units>Participants with P type event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Positive and Negative Syndrome Scale (PANSS) Total Score</title>
        <description>PANSS total score equals sum of the 30-items scores (range: 30-210). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree. Change in PANSS total score : total score at month 24 minus total score at randomization.Alleviation of psychotic symptoms are indicated by a negative change in PANSS total score.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Positive and Negative Syndrome Scale (PANSS) Total Score</title>
          <description>PANSS total score equals sum of the 30-items scores (range: 30-210). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree. Change in PANSS total score : total score at month 24 minus total score at randomization.Alleviation of psychotic symptoms are indicated by a negative change in PANSS total score.</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="15.4"/>
                    <measurement group_id="O2" value="-8.6" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the PANSS Positive Subscale Score</title>
        <description>PANSS Positive subscale score equals sum of the 7-items scores(range:7-49). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the PANSS Positive Subscale Score</title>
          <description>PANSS Positive subscale score equals sum of the 7-items scores(range:7-49). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree.</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.3"/>
                    <measurement group_id="O2" value="-2.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the PANSS Negative Subscale Score</title>
        <description>PANSS Negative subscale score equals sum of the 7-items scores(range:7-49). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree. Change in PANSS Negative subscale score:score at month 24 minus score at randomization. Alleviation of negative psychotic symptoms are indicated by a negative change score.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the PANSS Negative Subscale Score</title>
          <description>PANSS Negative subscale score equals sum of the 7-items scores(range:7-49). Each item has ( 1-7 units), 1 indicates &quot;absent&quot; psychosis symptom, and 7 - &quot;extreme&quot; symptom degree. Change in PANSS Negative subscale score:score at month 24 minus score at randomization. Alleviation of negative psychotic symptoms are indicated by a negative change score.</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="5.5"/>
                    <measurement group_id="O2" value="-1.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the PANSS Psychopathology Subscale Score</title>
        <description>PANSS psychopathology subscale score equals sum of the 16-items scores(range:16-112). Each item has ( 1-7 units),1= &quot;absent&quot; psychosis symptom, 7= &quot;extreme&quot; symptom degree.Change in PANSS psychopathology subscale:score at month 24 minus score at randomization. Alleviation of general psychopathology symptoms are indicated by a negative change score.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the PANSS Psychopathology Subscale Score</title>
          <description>PANSS psychopathology subscale score equals sum of the 16-items scores(range:16-112). Each item has ( 1-7 units),1= &quot;absent&quot; psychosis symptom, 7= &quot;extreme&quot; symptom degree.Change in PANSS psychopathology subscale:score at month 24 minus score at randomization. Alleviation of general psychopathology symptoms are indicated by a negative change score.</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="7.7"/>
                    <measurement group_id="O2" value="-4.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score</title>
        <description>CGI-S score is accessed on a seven-graded scale ranging from most extremely ill/ very much worse (7) to normal/very much improved (1) , 1 is best. Change : score at month 24 minus score at randomization.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score (not related to CGI-S), and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score</title>
          <description>CGI-S score is accessed on a seven-graded scale ranging from most extremely ill/ very much worse (7) to normal/very much improved (1) , 1 is best. Change : score at month 24 minus score at randomization.</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score (not related to CGI-S), and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.9"/>
                    <measurement group_id="O2" value="-0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q SF) Total Score</title>
        <description>Q-LES-Q total score is the sum of the 16 times of Q-LES-Q SF(range:16-80).Each item has a 5 point satisfaction level scale:from 1=very poor(worst value) to 5=very good(best).Larger values indicate a higher perceived quality of life enjoyment and satisfaction.Change in Q-LES-Q total score:total score at month 24 minus total score at randomization</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q SF) Total Score</title>
          <description>Q-LES-Q total score is the sum of the 16 times of Q-LES-Q SF(range:16-80).Each item has a 5 point satisfaction level scale:from 1=very poor(worst value) to 5=very good(best).Larger values indicate a higher perceived quality of life enjoyment and satisfaction.Change in Q-LES-Q total score:total score at month 24 minus total score at randomization</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="11.6"/>
                    <measurement group_id="O2" value="2.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Personal Evaluation of Transitions in Treatment (PETiT) Total Score</title>
        <description>PETiT total score is the sum of the 30 items of PETiT questionnaire(range:0-60) on subjects perceived well-being, adherence, tolerability, satisfaction with treatment. Each item is rated by participant with a 3 point frequency scale:2=often, 1=sometimes, 0=never.Change in PETiT total score: total score at month 24 minus total score at randomization</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Personal Evaluation of Transitions in Treatment (PETiT) Total Score</title>
          <description>PETiT total score is the sum of the 30 items of PETiT questionnaire(range:0-60) on subjects perceived well-being, adherence, tolerability, satisfaction with treatment. Each item is rated by participant with a 3 point frequency scale:2=often, 1=sometimes, 0=never.Change in PETiT total score: total score at month 24 minus total score at randomization</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="6.2"/>
                    <measurement group_id="O2" value="0.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses of Schizophrenia or Schizoaffective Disorder</title>
        <description>Relapse is defined as a hospital stay for psychiatric symptoms or a 2-point increase from baseline in the CGI severity score. CGI-S score ranges from 0-7 with 0 = Not Assessed, 1 = Normal, not at all and 7 = Among the most extremely ill subjects.</description>
        <time_frame>At Month 24</time_frame>
        <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapses of Schizophrenia or Schizoaffective Disorder</title>
          <description>Relapse is defined as a hospital stay for psychiatric symptoms or a 2-point increase from baseline in the CGI severity score. CGI-S score ranges from 0-7 with 0 = Not Assessed, 1 = Normal, not at all and 7 = Among the most extremely ill subjects.</description>
          <population>The intention-to-treat for psychiatric assessments (ITTP) analysis included all randomized participants who had a valid baseline and at least 1 post baseline assessment of PANSS total score, and received at least 1 dose of study medication.</population>
          <units>Relapses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Simpson-Angus Scale (SAS) Total Score</title>
        <description>SAS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4, higher scores indicate greater severity of Parkinsonian symptoms. Change : total score at month 24 minus total score at randomization. Increase in Change of total score indicates an increase in extrapyramidal motor symptoms.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Simpson-Angus Scale (SAS) Total Score</title>
          <description>SAS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4, higher scores indicate greater severity of Parkinsonian symptoms. Change : total score at month 24 minus total score at randomization. Increase in Change of total score indicates an increase in extrapyramidal motor symptoms.</description>
          <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.1"/>
                    <measurement group_id="O2" value="-0.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Barnes Akathisia Rating Scale (BARS) Global Score</title>
        <description>BARS global score is the 4th individual-item score on the BARS scale, the Global Assessment of Akathisia, with the score ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Change : score at month 24 minus score at randomization. Increase in Change of BARS global score indicates an increase in akathisia.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Barnes Akathisia Rating Scale (BARS) Global Score</title>
          <description>BARS global score is the 4th individual-item score on the BARS scale, the Global Assessment of Akathisia, with the score ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Change : score at month 24 minus score at randomization. Increase in Change of BARS global score indicates an increase in akathisia.</description>
          <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
          <units>units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Abnormal Involuntary Movement Scale (AIMS) Total Score</title>
        <description>AIMS total score is the sum of the 10 individual-item scores(range:0-40), with the score for each item ranging from 0 to 4. Change : total score at month 24 minus total score at randomization. Increase in Change of total score indicates an increase in abnormal voluntary movements. The lower score means lower intensity of abnormal voluntary Movements. 0 is best, 4 is worst. Increase in Change of total score indicates an increase in abnormal voluntary Movements.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Abnormal Involuntary Movement Scale (AIMS) Total Score</title>
          <description>AIMS total score is the sum of the 10 individual-item scores(range:0-40), with the score for each item ranging from 0 to 4. Change : total score at month 24 minus total score at randomization. Increase in Change of total score indicates an increase in abnormal voluntary movements. The lower score means lower intensity of abnormal voluntary Movements. 0 is best, 4 is worst. Increase in Change of total score indicates an increase in abnormal voluntary Movements.</description>
          <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.5"/>
                    <measurement group_id="O2" value="0.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potential Extrapyramidal Symptoms (EPS)</title>
        <description>Number of participants with adverse events potentially associated with EPS collected by MedDRA Preferred Terms as akathisia, bradykinesia, drooling, dyskinesia, dystonia, extrapyramidal disorder, grimacing, muscle rigidity, parkinsonism, restlessness, tardive dyskinesia, tremor</description>
        <time_frame>From start of the study treatment to last dose plus 30 days</time_frame>
        <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potential Extrapyramidal Symptoms (EPS)</title>
          <description>Number of participants with adverse events potentially associated with EPS collected by MedDRA Preferred Terms as akathisia, bradykinesia, drooling, dyskinesia, dystonia, extrapyramidal disorder, grimacing, muscle rigidity, parkinsonism, restlessness, tardive dyskinesia, tremor</description>
          <population>The Safety analysis set included all randomized participants who received at least 1 dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine Fumarate</title>
          <description>Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>Risperidone - flexibly dosed (2 - 8 mg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diastolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pancreatic Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pilonidal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Drug Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Multiple Drug Overdose Accidental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Therapeutic Agent Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Respiratory Fume Inhalation Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Qt Prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix Carcinoma Stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Metastases To Liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Oesophageal Adenocarcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Schizoaffective Disorder</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Schizophrenia, Paranoid Type</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Drug Abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Affective Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Homicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Drug Dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Flashback</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Self Injurious Behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Somatic Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Substance Abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Suicidal Behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Substance Abuser</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="476" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="368" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Extrapyramidal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="496"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="496"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agrees to collaborate in good faith with AstraZeneca with regards to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>AZTrial_Results_Posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

